Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Business Wire - Mon Mar 9, 5:59AM CDT

Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program

BMY : 59.40 (-1.21%)
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Business Wire - Fri Mar 6, 8:59PM CST

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical...

BMY : 59.40 (-1.21%)
BMY
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks StockStory - Wed Mar 4, 9:33PM CST

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

BMY : 59.40 (-1.21%)
Bristol Myers Squibb Announces Dividend Business Wire - Mon Mar 2, 3:16PM CST

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the...

BMY : 59.40 (-1.21%)
Bristol-Myers Squibb Co_ logo on building-by tatu Campelo via iStock
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq? Barchart - Fri Feb 27, 10:16AM CST

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

$NASX : 22,673.13 (-0.11%)
LLY : 993.00 (-0.83%)
BMY : 59.40 (-1.21%)
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Business Wire - Thu Feb 26, 5:59AM CST

Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (“PFS”) and overall survival (“OS”) in an interim analysis of a Phase 3 trial (NCT06382142) conducted...

BMY : 59.40 (-1.21%)
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity FinancialNewsMedia - Tue Feb 24, 8:35AM CST

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

HELP : 5.55 (-3.31%)
CMPS : 6.94 (-6.72%)
PFE : 27.04 (-0.44%)
TAK : 18.02 (-1.04%)
BMY : 59.40 (-1.21%)
BMY
3 Reasons to Avoid BMY and 1 Stock to Buy Instead StockStory - Mon Feb 23, 10:04PM CST

3 Reasons to Avoid BMY and 1 Stock to Buy Instead

BMY : 59.40 (-1.21%)
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference Business Wire - Mon Feb 23, 3:16PM CST

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 46 th Annual Health Care Conference on Monday, March 2, 2026. The...

BMY : 59.40 (-1.21%)
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia Business Wire - Mon Feb 23, 5:59AM CST

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints

BMY : 59.40 (-1.21%)

Barchart Exclusives

Should You Buy Vertiv Stock Before March 23? Barchart - 3 minutes ago
Vertiv stock surged to an all-time high on news of its inclusion in the S&P 500. Here's what investors need to know. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot